VectivBio jumps on 'orphan drug' tag for graft-versus-host disease drug

VectivBio Holding AG

24/06/2021 13:50

** Shares of drug developer VectivBio Holding AG  VECT.O 
rise 10.7% to $14 premarket
    ** U.S. FDA grants 'orphan drug' designation to co's
experimental therapy, apraglutide, for treatment of acute
graft-versus-host disease  urn:newsml:reuters.com:*:nGNX7vDnM7
    ** Orphan status is granted to treatments for rare diseases
or disorders that affect fewer than 200,000 people in the United
States
    ** VectivBio plans to initiate mid-stage trial evaluating
apraglutide for treatment of graft-versus-host disease in Q1 of
2022
    ** Graft-versus-host disease is a multisystem disorder that
is a common complication of stem cell transplants - where the
transplanted immune system attacks the recipient's body

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))